Evidence that the degree of interstitial inflammation and anemia correlates with graft survival brings into question the traditional management of proteinuria, which consists primarily of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers as the first-line treatment. This evidence concerns the gene ACE and anemia.